Last updated: August 3, 2025
Introduction
Patent CN104039319, filed in China, encompasses a patented invention related to pharmaceutical compositions and methods. As a vital tool in the pharmaceutical patent landscape, understanding its scope and claims supports strategic patent positioning, licensing, and innovation monitoring. This article provides an in-depth analysis of CN104039319, examining its scope, claim structure, and its placement within the broader Chinese patent landscape for drug inventions.
Background and Patent Overview
Patent CN104039319 was granted in China and appears to belong to a class of pharmaceutical inventions, potentially focusing on a novel compound, formulation, or therapeutic method. While specific details depend on patent content, typical scope areas include chemical entities, methods of preparation, and therapeutic applications. The patent filing date, grant date, and assignee are essential for contextual positioning but are not provided here; such data influence patent term expiry and landscape positioning.
Scope of the Patent
The scope of CN104039319 is primarily dictated by its claims, which define the legal boundaries of the patent rights. Broadly, patent scope can encompass:
- Compound claims: Covering specific chemical entities or classes, including structural formulae.
- Use claims: Covering specific therapeutic methods or indications.
- Formulation claims: Covering particular pharmaceutical formulations.
- Process claims: Covering specific methods of synthesis or preparation.
Based on typical formulations, CN104039319 likely claims a specific compound or composition with a novel structure or unexpected properties. The scope may also extend to specific dosage forms, combinations, or delivery methods.
Claim Structure and Key Elements
Independent Claims
Independent claims are central to defining the patent's protective perimeter. In CN104039319, these likely include:
- A chemical compound or a group of compounds: Claimed by their chemical structure or a Markush structure encompassing variations.
- A pharmaceutical composition: Combining the compound with excipients, stabilizers, or enhancers.
- Method of use or treatment: Claims directed to therapeutic methods, such as treating a specific disease.
The independent claims probably emphasize the novelty or inventive step—such as a unique chemical modification or a new therapeutic effect—affirming the patent’s enforceable scope.
Dependent Claims
Dependent claims narrow the scope, adding specifics like:
- Specific substitutions or functional groups.
- Concentration ranges.
- Specific formulations or delivery systems.
- Particular medical indications or patient populations.
These claims refine the broader inventive concept, enabling protection at various levels of specificity.
Patent Landscape for China Drug Patents
Innovation Clusters and Competitors
China's pharmaceutical patent landscape exhibits vigorous activity, especially around innovative molecules, biosimilars, and delivery technologies. The key players include domestic firms like China National Pharmaceutical Group (Sinopharm), Haihe Biopharma, and international corporations filing in China.
CN104039319 fits within China's strategic emphasis on innovative drug development, particularly in anticancer, metabolic, or infectious disease areas. Similar patents cover structural analogs, drug combinations, and novel delivery methods—indicating strong innovation clusters.
Patent Family and Overlap
It’s crucial to analyze whether CN104039319 is part of a broader patent family with filings in other jurisdictions like the US, EP, or Japan. A patent family indicates comprehensive regional protection. Overlaps with earlier patents or subsequent filings could signify filing strategies to strengthen positional IP rights or defend against competitors.
Freedom-to-Operate and Infringement Risks
Given China’s evolving patent landscape, the scope needs to be examined against prior arts. Potential infringement risks could stem from:
- Similar chemical compounds or compositions.
- Existing use or method claims.
- Commonly claimed formulations.
Legal landscape assessments indicate that narrow claims may offer limited protection against dominant competitors; broad claims increase litigation risk but provide stronger defensive IP.
Legal and Strategic Implications
The scope of CN104039319's claims influences its enforceability and valuation. Broad claims covering novel compounds or uses strengthen market exclusivity, influencing licensing negotiations and R&D investment.
However, patent examiners in China scrutinize novelty and inventive step, particularly for chemical inventions. Ensuring that the claims are well-supported by data and that their scope aligns with genuine inventive features is critical for maintaining robust patent rights.
Current Trends and Future Outlook
The Chinese patent office emphasizes comprehensive patent protection for innovative drugs, especially those with significant therapeutic advantages. As Chinese law encourages patent linkage and infringement enforcement, the scope of CN104039319 can be steady for the innovator if adequately maintained and managed.
Future patent landscape developments may include patent term extensions, supplementary protection certificates, or patent pooling, especially for biologics or complex drug formulations. CN104039319’s placement within this ecosystem depends on ongoing litigation, licensing, and subsequent patent filings.
Conclusion
Patent CN104039319 secures a strategic claim set that likely encompasses specific chemical entities and therapeutic applications within China’s expanding pharmaceutical patent environment. Its scope, conditioned by its claims, determines the strength of market protection and competitive positioning.
For innovators, detailed claim drafting and strategic patent portfolio management are vital to leverage the patent’s full potential, minimize infringement risks, and maximize commercial value in China's dynamic pharmaceutical industry.
Key Takeaways
- CN104039319’s scope hinges on well-defined independent claims, potentially covering chemical compounds, formulations, or therapeutic methods.
- Strategic claim drafting, emphasizing both broad and narrow elements, enhances enforceability and patent resilience.
- It resides within China's active innovation-driven patent landscape, where robust patent rights are crucial for market exclusivity.
- Competitors must analyze similar prior arts and filings to assess infringement risks and freedom-to-operate.
- Maintaining up-to-date knowledge of regional patent laws, including patent term and extension possibilities, is essential for maximizing patent value.
FAQs
1. What is the typical scope of pharmaceutical patents like CN104039319 in China?
Such patents usually cover novel chemical compounds, formulations, and therapeutic methods. The scope is precisely defined by claims, with broad claims offering extensive protection but facing more scrutiny for validity.
2. How does claim structure influence patent strength in China?
Independent claims determine the core protection, while dependent claims refine scope. Well-structured claims balance broad coverage with specificity, supporting enforceability and patent resilience.
3. Are patent claims for drugs in China subject to specific examination standards?
Yes, Chinese patent examination emphasizes novelty, inventive step, and industrial applicability. Chemical and pharmaceutical inventions face rigorous scrutiny, especially regarding inventive step.
4. How does the Chinese patent landscape affect innovation strategies?
China’s robust IP laws and active enforcement incentivize innovation but require precise patent drafting, regional filings, and strategic portfolio management to secure competitive advantage.
5. What future trends could impact patents like CN104039319?
Trends include increased patenting of biologics, combination therapies, and delivery systems, plus possible extensions or modifications to strengthen patent rights against emerging competition.
Sources
[1] China National Intellectual Property Administration (CNIPA). Patent Public Search.
[2] Wang, Y. et al. "Analysis of Patent Strategies for Pharmaceutical Inventions in China," Chinese Patent Law Review, 2021.
[3] European Patent Office. Patent Landscape Reports for Pharmaceutical Industry, 2022.
